China Real World Study on Patient Baseline Characteristics and Treatment Pattern of Endometrial Cancer (PEC)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48394
• EU PAS number:
  EUPAS48393
• Study ID:
  48394
• Official title and acronym:
  China Real World Study on Patient Baseline Characteristics and Treatment Pattern of Endometrial Cancer (PEC)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study status:
  Ongoing

Research institutions and networks

Institutions

Qilu Hospital of Shandong University

First Affiliated Hospital of Xi 'an Jiaotong University Xian, China, The First Affiliated Hospital, Sun Yat-sen University Guangzhou, China, Nanjing Maternity and Child Health Care Hospital Nanjing, China, Xiangya Hospital Central South University Changsha, China, Chongqing Cancer Hospital Chongqing, China, Qingdao Central Hospital Qingdao, China, Henan Cancer Hospital Zhengzhou, China

Study timelines

Date when funding contract was signed

Actual: 27/10/2020

Study start date

Actual: 16/06/2021

Date of final study report

Planned: 31/10/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

MSD (China) Holding Co., Ltd.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable